NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
08/31/2024
Back to search
Official data from USPTO
MOLECULAR PHARMACEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MOLECULAR PHARMACEUTICS
ST13
US500000076463106Class
16
Filing
76463106
Registration
2890503
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
08/31/2024
Trademark type
Word
Nice classes
16
Filing date
10/30/2002
Registration date
09/28/2004
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/31/2024
Last transaction
08/31/2024
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Supplemental Register
Filing basis
Intent to use
First use anywhere
09/01/2003
First use in commerce
09/01/2003
Drawing code
1
Owner type
99
Owner location
Washington, DC
Examiner
NELSON, EDWARD
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
A. S. (pessoa física)
Representatives
Gregory M. Stone Whiteford, Taylor & Preston, LLP
Technical classification
Nice Classes
Class 16
Vienna Codes
No Vienna codes available.
Goods and services
Class 16
SCIENTIFIC MAGAZINE ISSUED PERIODICALLY IN THE FIELD OF MOLECULAR AND CELLULAR BIOLOGYPOLYMER AND MATERIALS SCIENCEPHARMACEUTICAL CHEMISTRY
Publications
History of USPTO decisions and trademark events.
27 publications found
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
08/31/2024
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
08/31/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/31/2024
E89R
TEAS SECTION 8 & 9 RECEIVED
06/19/2024
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - MAILED
07/24/2015
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
07/24/2015
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
07/24/2015
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
07/24/2015
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
03/27/2015
ES7R
TEAS SECTION 7 REQUEST RECEIVED
03/16/2015
PR89
POST REGISTRATION ACTION MAILED - SEC. 8 & 9
09/29/2014
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/29/2014
E89R
TEAS SECTION 8 & 9 RECEIVED
09/18/2014
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
06/03/2010
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/03/2010
ES8R
TEAS SECTION 8 RECEIVED
05/21/2010
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
09/28/2004
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
07/09/2004
CNSL
LETTER OF SUSPENSION MAILED
11/10/2003
IUAA
USE AMENDMENT ACCEPTED
11/10/2003
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
10/02/2003
IUAF
USE AMENDMENT FILED
09/11/2003
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/11/2003
PAPER RECEIVED
09/11/2003
CNRT
NON-FINAL ACTION MAILED
04/10/2003
DOCK
ASSIGNED TO EXAMINER
03/25/2003
Continuous trademark protection
Get notified about every new filing that threatens MOLECULAR PHARMACEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.